Large-cap health care company Moderna has moved -2.4% this afternoon, reaching $101.38 per share. In contrast, the average analyst target price for the stock is $180.76.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company is based in the United States.
What to Consider if You Are Thinking of Buying Moderna:
-
Moderna has moved -18.0% over the last year.
-
MRNA has a forward P/E ratio of -19.6 based on its EPS guidance of -5.16.
-
Over the last 5 years, earnings per share (EPS) have been growing at a compounded average rate of 9.6%.
-
The company has a price to earnings growth (PEG) ratio of 0.52.
-
Its Price to Book (P/B) ratio is 2.28
Moderna Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-24 | 4,981,000 | -400,000 | 5,381,000 | -61.3 |
| 2022-02-25 | 13,620,000 | -284,000 | 13,904,000 | 563.68 |
| 2021-02-26 | 2,027,000 | -68,000 | 2,095,000 | 590.63 |
| 2020-02-27 | -459,000 | -32,000 | -427,000 | -89.69 |
| 2019-02-06 | -330,865 | -105,766 | -225,099 |
Moderna's free cash flows have a decent average of $4.15 Billion over the last 5 years, but they are highly variable since their coefficient of variability is 2958439515.2%. The compounded average growth rate over this period is 0.0%.
